<DOC>
	<DOCNO>NCT02244190</DOCNO>
	<brief_summary>To establish bioequivalence new tipranavir oral solution formulation current tipranavir oral solution formulation follow single-dose administration . In case , 500 mg tipranavir coadministered 200 mg ritonavir .</brief_summary>
	<brief_title>Bioequivalence Two Different Oral Solutions Tipranavir Administered Combination With Ritonavir Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Healthy male female accord follow criterion base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥ 18 ≤ 55 year BMI ≥ 18.5 ≤ 29.9 kg/m2 ( Body Mass Index ) body weight &gt; 55 kg Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackout . Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy tipranavir ritonavir excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial drug trial Cytochrome P 450 ( CYP3A4 ) inhibit drug ( e.g . itraconazole , ketoconazole , protease inhibitor , erythromycin , clarithromycin , telithromycin , nefazodone , cyclosporin , verapamil , amiodarone , diltiazem ) , CYP3A4 induce drug ( e.g . St. John´s wort [ Hypericum perforatum ] , rifampin , dexamethasone ) CYP3A4 substrates ( e.g . triazolam , sertraline ) ; drug might reasonably influence result trial ( e.g . drug contain polyethylene glycol ) drug prolong QT/corrected QT interval interval ( base knowledge time protocol preparation ) within 14 day prior first administration trial drug trial Participation another trial investigational drug within two month prior administration trial drug trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke within 24 hour administration trial drug Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial drug trial ) Excessive physical activity ( within one week prior administration trial drug trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de Pointes ( TdP ) , e.g. , heart failure , hypokalaemia , family history Long QT Syndrome Known hypersensitivity antiretroviral drug ( market experimental use part clinical research study ) Personal family history coagulation bleed disorder bleed tendency Intake vitamin E within 14 day prior first drug administration trial trial Transaminase value ( ALT /AST ) great upper limit normal laboratory reference range screen For female subject : Pregnancy positive pregnancy test , plan become pregnant study within 1 month study completion No adequate contraception study 1 month study completion , i.e . follow : implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence ( least 1 month prior enrolment ) , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( incl . hysterectomy ) . Females vasectomise partner , sexually abstinent surgically sterile ask additionally use barrier contraception method ( e.g . condom , diaphragm spermicide ) . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>